EP1128832A4 - Compounds, compositions and methods for treating or preventing viral infections and associated diseases - Google Patents
Compounds, compositions and methods for treating or preventing viral infections and associated diseasesInfo
- Publication number
- EP1128832A4 EP1128832A4 EP99942288A EP99942288A EP1128832A4 EP 1128832 A4 EP1128832 A4 EP 1128832A4 EP 99942288 A EP99942288 A EP 99942288A EP 99942288 A EP99942288 A EP 99942288A EP 1128832 A4 EP1128832 A4 EP 1128832A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- treating
- compounds
- methods
- viral infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9747698P | 1998-08-21 | 1998-08-21 | |
| US97476P | 1998-08-21 | ||
| US11321298P | 1998-12-22 | 1998-12-22 | |
| US113212P | 1998-12-22 | ||
| US11932899P | 1999-02-09 | 1999-02-09 | |
| US119328P | 1999-02-09 | ||
| US13558699P | 1999-05-24 | 1999-05-24 | |
| US13558599P | 1999-05-24 | 1999-05-24 | |
| US135586P | 1999-05-24 | ||
| US135585P | 1999-05-24 | ||
| PCT/US1999/018785 WO2000010573A1 (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1128832A1 EP1128832A1 (en) | 2001-09-05 |
| EP1128832A4 true EP1128832A4 (en) | 2003-03-05 |
Family
ID=27536838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99942288A Withdrawn EP1128832A4 (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1128832A4 (en) |
| JP (1) | JP2002523371A (en) |
| KR (1) | KR20010099623A (en) |
| CN (1) | CN1325309A (en) |
| AU (1) | AU743411B2 (en) |
| BR (1) | BR9913157A (en) |
| CA (1) | CA2341970A1 (en) |
| ID (1) | ID27787A (en) |
| IL (1) | IL141456A0 (en) |
| WO (1) | WO2000010573A1 (en) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200103562T2 (en) * | 1999-06-10 | 2002-04-22 | Warner-Lambert Company | Rhodanine derivatives for use in the method of preventing amyloid protein aggregation and imaging amyloid deposits |
| MXPA02002257A (en) | 1999-08-31 | 2002-09-30 | Maxia Pharmaceuticals Inc | Benzylidene thiazolidinediones and analogues and their use in the treatment of diabetes. |
| AU2001253206A1 (en) | 2000-04-05 | 2001-10-23 | Tularik, Inc. | Ns5b hcv polymerase inhibitors |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| YU23503A (en) * | 2000-09-29 | 2006-03-03 | Neurogen Corporation | High afinity small molecule c5a receptor modulators |
| CA2440184A1 (en) | 2001-03-07 | 2002-09-19 | Incyte San Diego, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| EP1377559A4 (en) | 2001-03-08 | 2005-09-28 | Incyte San Diego Inc | Rxr activating molecules |
| GB2376944A (en) * | 2001-05-18 | 2002-12-31 | Pantherix Ltd | Polycyclic heterocyclic compounds and their therapeutic use |
| US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| EP1429759A4 (en) | 2001-09-26 | 2004-12-15 | Bristol Myers Squibb Co | Compounds useful for treating hepatitus c virus |
| JP2005513026A (en) | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | Hypercholesterolemia, dyslipidemia and other metabolic disorders; N-substituted heterocycles to treat cancer and other diseases |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| US20060281798A1 (en) * | 2002-05-17 | 2006-12-14 | Qlt Inc. | Methods of using thiazolidinedithione derivatives |
| ATE503764T1 (en) | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | HEPATITIS C VIRUS INHIBITORS |
| AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| ATE481106T1 (en) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | HETEROCYCLIC SULFONAMIDE HEPATITIS C VIRUS INHIBITORS |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7041690B2 (en) | 2002-07-01 | 2006-05-09 | Pharmacia & Upjohn Company, Llc | Inhibitors of HCV NS5B polymerase |
| BR0305259A (en) | 2002-07-01 | 2004-10-05 | Upjohn Co | Hcv ns5b polymerase inhibitors |
| FR2845000B1 (en) * | 2002-09-27 | 2005-05-27 | Oreal | USE OF A HETEROCYCLIC COMPOUND OR ONE OF ITS SALTS FOR STIMULATING OR INDUCING THE GROWTH OF HAIR AND / OR BRAKING THEIR FALL |
| AU2003277162C1 (en) * | 2002-09-30 | 2009-12-24 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| US7235573B2 (en) | 2002-09-30 | 2007-06-26 | The Regents Of The University Of California | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors |
| US20060276520A1 (en) * | 2002-11-13 | 2006-12-07 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
| WO2004094452A2 (en) | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| EP1651226B1 (en) | 2003-07-11 | 2010-02-24 | Proteologics, Inc. | Ubiquitin ligase inhibitors and methods related thereto |
| FR2858324A1 (en) * | 2003-07-30 | 2005-02-04 | Centre Nat Rech Scient | Composition used for treating microbial infections, effective particularly against rifampicin-resistant bacteria, contain new or known 5-(heterocyclylmethylene)-thiazolidine derivatives |
| US7112601B2 (en) | 2003-09-11 | 2006-09-26 | Bristol-Myers Squibb Company | Cycloalkyl heterocycles for treating hepatitis C virus |
| US7566732B2 (en) | 2003-10-28 | 2009-07-28 | Rigel Pharmaceuticals, Inc. | Rhodanine compositions for use as antiviral agents |
| US7026339B2 (en) | 2003-11-07 | 2006-04-11 | Fan Yang | Inhibitors of HCV NS5B polymerase |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1718608B1 (en) | 2004-02-20 | 2013-07-17 | Boehringer Ingelheim International GmbH | Viral polymerase inhibitors |
| DE602005013922D1 (en) | 2004-02-24 | 2009-05-28 | Japan Tobacco Inc | CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITOR |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| EP1879885A1 (en) | 2005-05-04 | 2008-01-23 | F. Hoffmann-Roche AG | Heterocyclic antiviral compounds |
| WO2006138118A2 (en) * | 2005-06-15 | 2006-12-28 | New York Blood Center | Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| EP2019830A4 (en) * | 2006-05-04 | 2011-01-19 | Inst Hepatitis & Virus Res | Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus |
| CN101573370B (en) | 2006-10-10 | 2013-09-11 | 美迪维尔公司 | HCV nucleoside inhibitor |
| WO2008082537A2 (en) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Compounds for modulating integrin cd11b/cd18 |
| AP2874A (en) | 2007-06-29 | 2014-03-31 | Gilead Sciences Inc | Antiviral compounds |
| CA2692145C (en) | 2007-06-29 | 2015-03-03 | Gilead Sciences, Inc. | Antiviral compounds |
| JP2011502998A (en) | 2007-11-01 | 2011-01-27 | ザ ユーエイビー リサーチ ファウンデイション | Treatment and prevention of viral infection |
| US20110015158A1 (en) | 2007-12-11 | 2011-01-20 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| US7947717B2 (en) | 2008-07-18 | 2011-05-24 | Burnham Institute For Medical Research | Inhibitors of lethal factor protease |
| BRPI0922366B8 (en) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | compound, pharmaceutical composition and use of a compound |
| US8865756B2 (en) | 2008-12-03 | 2014-10-21 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
| MX2012005528A (en) | 2009-11-14 | 2012-06-12 | Hoffmann La Roche | Biomarkers for predicting rapid response to hcv treatment. |
| SG181104A1 (en) | 2009-12-02 | 2012-07-30 | Hoffmann La Roche | Biomarkers for predicting sustained response to hcv treatment |
| EP2515903A4 (en) * | 2009-12-23 | 2013-07-10 | Peter Maccallum Cancer Inst | Compounds, preparations and uses thereof |
| EP2575866A4 (en) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | Inhibitors of hcv ns5a |
| KR101159000B1 (en) * | 2010-06-18 | 2012-06-21 | (주) 에빅스젠 | Novel rhodanine derivative, process for preparing the same and pharmaceutical composition for preventing or treating AIDS comprising the same |
| US9023876B2 (en) | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| US9255088B2 (en) | 2010-08-11 | 2016-02-09 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| WO2012175581A1 (en) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| CN103917541B (en) | 2011-10-10 | 2016-08-17 | 弗·哈夫曼-拉罗切有限公司 | Antiviral compound |
| US9133170B2 (en) | 2011-12-16 | 2015-09-15 | Hoffmann-La Roche Inc. | Inhibitors of HCV NS5A |
| CA2856179C (en) | 2011-12-20 | 2017-02-28 | F. Hoffmann-La Roche Ag | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
| SI2794628T1 (en) | 2011-12-20 | 2017-07-31 | Riboscience Llc | 4'-azido-3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication |
| BR112014015582A8 (en) | 2012-02-24 | 2017-07-04 | Hoffmann La Roche | antiviral compounds |
| WO2013142346A1 (en) | 2012-03-23 | 2013-09-26 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| ES2766751T3 (en) | 2012-04-20 | 2020-06-15 | Gb006 Inc | Compositions for the regulation of integrins |
| US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
| RU2015132550A (en) | 2013-01-23 | 2017-03-02 | Ф. Хоффманн-Ля Рош Аг | TRIAZOLE ANTIVIRAL DERIVATIVES |
| CA2900319A1 (en) | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| RU2534613C2 (en) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them |
| US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
| EA035301B1 (en) | 2013-05-16 | 2020-05-26 | Рибосайенс Ллк | 4'-fluoro-2'-methyl substituted nucleoside derivatives |
| US9249176B2 (en) | 2013-05-16 | 2016-02-02 | Riboscience Llc | 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication |
| EP3684374A4 (en) | 2017-09-21 | 2021-06-16 | Riboscience LLC | 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
| KR101893988B1 (en) | 2018-05-16 | 2018-08-31 | (주)에빅스젠 | Pharmaceutical composition comprising Rhodanine derivative for preventing or treating AIDS |
| WO2023161427A1 (en) | 2022-02-24 | 2023-08-31 | Eisbach Bio Gmbh | Viral combination therapy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993021934A1 (en) * | 1992-05-01 | 1993-11-11 | Commonwealth Scientific And Industrial Research Organisation | Heteropolytungstates in the treatment of flavivirus infections |
| WO1998020013A1 (en) * | 1996-11-07 | 1998-05-14 | Andreas Johannes Kesel | New knoevenagel condensation products, method for their production and their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909467A (en) * | 1958-07-09 | 1959-10-20 | Us Vitamin Pharm Corp | 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione |
| US3888984A (en) * | 1972-03-13 | 1975-06-10 | Lilly Industries Ltd | Oxazole and imidazole derivatives as antifungal agents |
| AU6610081A (en) * | 1980-01-24 | 1981-07-30 | Senju Pharmaceutical Co., Ltd. | Thiazolidine derivatives |
| US4367234A (en) * | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
| US5693337A (en) * | 1994-07-13 | 1997-12-02 | Wakamoto Pharmaceutical Co., Ltd. | Stable lipid emulsion |
| US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
-
1999
- 1999-08-19 KR KR1020017002117A patent/KR20010099623A/en not_active Application Discontinuation
- 1999-08-19 ID IDW20010428A patent/ID27787A/en unknown
- 1999-08-19 JP JP2000565894A patent/JP2002523371A/en active Pending
- 1999-08-19 CN CN99812282A patent/CN1325309A/en active Pending
- 1999-08-19 EP EP99942288A patent/EP1128832A4/en not_active Withdrawn
- 1999-08-19 CA CA002341970A patent/CA2341970A1/en not_active Abandoned
- 1999-08-19 IL IL14145699A patent/IL141456A0/en unknown
- 1999-08-19 WO PCT/US1999/018785 patent/WO2000010573A1/en not_active Application Discontinuation
- 1999-08-19 AU AU55702/99A patent/AU743411B2/en not_active Ceased
- 1999-08-19 BR BR9913157-9A patent/BR9913157A/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993021934A1 (en) * | 1992-05-01 | 1993-11-11 | Commonwealth Scientific And Industrial Research Organisation | Heteropolytungstates in the treatment of flavivirus infections |
| WO1998020013A1 (en) * | 1996-11-07 | 1998-05-14 | Andreas Johannes Kesel | New knoevenagel condensation products, method for their production and their use |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO0010573A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL141456A0 (en) | 2002-03-10 |
| AU5570299A (en) | 2000-03-14 |
| EP1128832A1 (en) | 2001-09-05 |
| CN1325309A (en) | 2001-12-05 |
| JP2002523371A (en) | 2002-07-30 |
| KR20010099623A (en) | 2001-11-09 |
| ID27787A (en) | 2001-04-26 |
| AU743411B2 (en) | 2002-01-24 |
| BR9913157A (en) | 2001-05-15 |
| WO2000010573A1 (en) | 2000-03-02 |
| CA2341970A1 (en) | 2000-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1128832A4 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
| EP1109580A4 (en) | Methods for treating or preventing viral infections and associated diseases | |
| EP1115286A4 (en) | Methods for treating or preventing viral infections and associated diseases | |
| AU1099000A (en) | Novel compounds and compositions for treating hepatitis c infections | |
| HK1023371A1 (en) | Compositions and methods for treating viral infections | |
| AP2000002010A0 (en) | Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof | |
| EP1109548A4 (en) | Compositions and methods for treating and preventing bone diseases using tocotrienols | |
| EP1051169A4 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
| ZA200003768B (en) | Methods and compositions for treating diseases and conditions of the eye. | |
| EP0920419A4 (en) | Compounds, compositions and methods for treating influenza | |
| AU7165498A (en) | Methods for treating viral infections | |
| AU2002324753A1 (en) | Composition and method for treating viral infection | |
| ZA200203435B (en) | Method and compositions for treating pulmonary diseases. | |
| EP1135137A4 (en) | Copolymer compositions for treating viral infections | |
| ZA977874B (en) | Pharmaceutical compositions for treating viral diseases | |
| AU2003237088A8 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
| MXPA03005526A (en) | Combination method for treating viral infections. | |
| PL345068A1 (en) | Novel compounds derived from α-d-xylose, preparation method and therapeutic use | |
| AU6798000A (en) | Compounds, compositions and methods for treating influenza | |
| AU3698199A (en) | Radioimmuno-pharmacon for treating the hiv-1 infection | |
| ZA200004856B (en) | Treatment of panic attacks. | |
| HU9900123D0 (en) | 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof | |
| EP1027352A4 (en) | Carbapenem antibacterial compounds, compositions and methods of treatment | |
| EP1032384A4 (en) | Carbapenem antibacterial compounds, compositions and methods of treatment | |
| IL149443A0 (en) | Compositions for treating viral diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010315 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20030122 |
|
| 17Q | First examination report despatched |
Effective date: 20040226 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20040908 |